Compare HIHO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | NCNA |
|---|---|---|
| Founded | 1990 | 1997 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.0M |
| IPO Year | 2002 | 2017 |
| Metric | HIHO | NCNA |
|---|---|---|
| Price | $0.85 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 25.6K |
| Earning Date | 12-14-2026 | 11-24-2026 |
| Dividend Yield | ★ 11.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.90 |
| 52 Week High | $2.21 | $4.55 |
| Indicator | HIHO | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 33.17 |
| Support Level | $0.74 | N/A |
| Resistance Level | $0.93 | $1.40 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 67.58 | 0.00 |
Highway Holdings Ltd manufactures and sells metal, plastic and electronic parts, components, subassemblies and finished products for OEMs and contract manufacturers. Its products are used in photocopiers, laser printers, print cartridges, electrical connectors, electrical circuits and other applications. The Company also offers tooling design and development, metal stamping, screen printing, plastic injection molding, pad printing and electronic assembly of printed circuit boards. It operates through metal stamping and mechanical OEM manufacturing operations and electronic OEM manufacturing operations, with metal stamping and mechanical OEM manufacturing operations generating maximum revenue. The Company generates maximum revenue from Europe.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.